2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1758 Functional CRISPR screening identifies IKZF3/aiolos as a determinant of glofitamab response in diffuse large B-cell lymphoma

Yidan Zhang, Qingqing Liu2, Xianhuo Wang, PhD3, Huilai Zhang, PhD4
1 Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
3 Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
4 Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Background:

Bispecific antibodies (BsAbs) have reshaped the treatment of hematologic malignancies, with several agents recently approved for B-cell lymphomas. Despite their substantial clinical efficacy, responses vary markedly among patients. Reliable biomarkers of treatment response remain lacking, and the tumor-intrinsic mechanisms driving this interpatient variability are poorly understood.

Methods:

To systematically identify genes that modulate DLBCL cell responses to glofitamab, we performed a drug-target-focused pooled CRISPR knockout screen in SU-DHL4 cells. The screen used a co-culture system with pan-T cells isolated from peripheral blood mononuclear cells (PBMCs) obtained from healthy donors.The library comprised 16,886 sgRNAs, including 16,240 sgRNAs targeting 1,624 established or potentially druggable genes (10 sgRNAs per gene) and 646 control sgRNAs. CRISPR-edited SU-DHL4 cells were co-cultured with T cells from healthy donors at an effector-to-target (E:T) ratio of 1:1 and treated with different concentrations of glofitamab for 7 days.

Results:

On day 7, cells were harvested for genomic DNA (gDNA) extraction, sgRNA amplification, and next-generation sequencing. We used the Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm to compare sgRNA abundance between glofitamab-treated and PBS-treated samples. sgRNAs with a negative log2 fold change were depleted following glofitamab treatment, indicating that knockout of their target genes increased sensitivity to glofitamab. These genes were therefore classified as negative regulators of the response to glofitamab. At 1 ng /mL, MAGeCK identified 9 genes with enriched sgRNAs and 9 with depleted sgRNAs. At 100 ng/mL, 27 and 12 genes showed sgRNA enrichment and depletion, respectively (FDR < 0.1). As expected, knockout of MS4A1, which encodes CD20, produced the strongest resistance phenotype in DLBCL cells, markedly attenuating glofitamab-induced T-cell cytotoxicity. Six candidate negative regulators were identified at both glofitamab concentrations: CD40, IFNGR2, TNFRSF10B, IFNGR1, JAK1 and JAK2. Four of these genes, IFNGR1, IFNGR2, JAK1 and JAK2, encode core components of the IFN-γ–JAK–STAT1 signaling pathway. To examine the involvement of this pathway, we quantified IFN-γ in the co-culture supernatants. IFN-γ levels were significantly higher following treatment with 100 ng/mL glofitamab than following treatment with 1 ng/mL glofitamab or PBS (P < 0.001 for both comparisons). Consistent with enhanced IFN-γ signaling, SU-DHL4 cells exposed to 100 ng/mL glofitamab exhibited increased intracellular phosphorylated STAT1 (pSTAT1) levels. We hypothesized that sustained IFN-γ signaling may promote a chronic inflammatory state associated with impaired T-cell function and reduced response to glofitamab.

In addition to core components of the IFN-γ–JAK–STAT1 pathway (IFNGR1, IFNGR2, JAK1 and JAK2), IKZF3 emerged as a prominent candidate negative regulator in the high-dose screen. IKZF3 did not meet the significance threshold in the low-dose screen but became a significant hit under the high-dose condition. This concentration-dependent pattern suggests that IKZF3 may facilitate a tumor-intrinsic adaptive state under glofitamab-induced selective pressure. To validate the screening results, we generated IKZF3-knockout (IKZF3-KO) SU-DHL4 and U-2932 cells using IKZF3-targeting sgRNAs. We isolated two independent single-cell clones harboring biallelic frameshift mutations, both of which showed markedly reduced Aiolos protein levels. WT and IKZF3-KO cells were then co-cultured with T cells for 24 h at six concentrations of glofitamab. Glofitamab induced dose-dependent cytotoxicity in both genotypes, with IKZF3-KO cells exhibiting substantially greater lysis than their WT counterparts. Together, these findings identify IKZF3 as a tumor-intrinsic determinant of glofitamab response in DLBCL.

Conclusions:

Our drug-target-focused CRISPR screen uncovered tumor-intrinsic regulators of glofitamab response and identified IKZF3/Aiolos as a negative regulator of treatment sensitivity in DLBCL. IKZF3 loss enhanced glofitamab-mediated cytotoxicity across two DLBCL cell lines, supporting further evaluation of Aiolos as a predictive biomarker and potential therapeutic target. Furthermore, given that IKZF3 is a known target of IMiDs/CELMoDs, these results provide a strong rationale for combining Aiolos-degrading agents with glofitamab to overcome resistance in DLBCL.

Yidan Zhang: No relevant conflicts of interest to declare.